ACR16 Day 4 Ends with Rheumatology Roundup Save

Jack Cush, MD

Nov 16, 2016 5:09 pm

The final day of the 2016 annual ACR meeting saw the return of "Rheumatology Round-up" at 7:30am in Hall D.

Drs. Jack Cush and Artie Kavanaugh started with announcing that this was the 80th annual scientific session for the ACR and that this meeting had over 17,000 attendees, nearly 3250 abstracts and over 200 sessions.

Round-up continues to be popular with over 3,000 members rising to hear the closing comments of Cush and Kavanaugh, who state their goal is to provide comments on what they consider some of the most novel or clinically impactful presentations at the meeting.

Here is a synopsis of the abstracts covered during this meeting review session:

Abstract #	Author	Title	Comment
1725	Metayas	Combination Therapy of Apremilast and Biologic Agent As a Safe Option of Psoriatic Arthritis and Psoriasis	22 patients on biologics who had apremilast added to treat their Pso/PsA
1018	Dai	Dietary Intake of Fiber and Risk of Knee Osteoarthritis	High fiber intake may reduce risk of OA
56	Boehler	A Systems Biology Approach to Investigating Beneficial Effects of Endurance Exercise in Myositis Patients	mig o RNA linked to muscle wasting
448	Peter	Cross-Cultural and Construct Validity of the Animated Activity Questionnaire to Assess Activity Limitations in Patients with Hip and Knee Osteoarthritis in Different Languages	Quality measure review of preganancy counseling for patients taking mycopheonolate
19L	Goll	Biosimilar Infliximab (CT-P13) Is Not Inferior to Originator Infliximab: Results from a 52-Week Randomized Switch Trial in Norway	biosimilar to infliximab shown not to be inferior to originator in multiple inflammatory conditions in Norway
2185	Hootman	Prevalence and Trends in Prescribed Opioid Use Among US Adults with Arthritis, 2008-2013, Medical Expenditure Panel Survey	CDC poster on changes in the opioid use in the USA
4L	Deodhar	Efficacy and Safety Results of Guselkumab, an Anti-IL23 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis over 24 Weeks: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study	Guselkumab an IL-23 inhibitor is very effective in 149 patients with PsA
3006	Bracaglia	IFN-Gamma (IFNγ), IFNγ-Induced Chemokines and Other Biomarkers in Macrophage Activation Syndrome (MAS)	Interferon gamma drives macrophage activation syndrome
1L	Husni	The Cardiovascular Safety of Celecoxib Versus Ibuprofen or Naproxen in 24,081 Patients with Osteoarthritis or Rheumatoid Arthritis	PRECISION study shows celecoxib to be safe and naproxen not to be as cardioprotective as it once was.
911	Stone	Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: Primary and Secondary Outcomes from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial	Tocilizumab shown to be superior in sustaine remissions and steroid sparing in GCA patients
2048	Clowse	Evaluating Transfer of Certolizumab Pegol into Breast Milk: Results from a Prospective, Postmarketing, Multicenter Pharmacokinetic Study	CRADLE lactation study of 18 women on CZP and showed 56% had no detectable CZP levels in children breast fed by moms receiving CZP
2049	Vinet	Serious Infections in RA Offspring Exposed to Tumor Necrosis Factor Inhibitors	Over 2000 RA patients on TNFi during pregnancy and no sigificant increased risk of infection in their newborn offspring.
2001	Juo	Perioperative Use of Synthetic Disease-Modifying Anti-Rheumatic Drugs or Tumor Necrosis Factor α Inhibitors Does Not Associate with Increased Rates of Post-Operative Infections	VA study of RA patients havin surgery shows you need not stop MTX, HCQ, LEF or TNFi before surgery and no increase in perioperative infections.
89	Deal	2015 ACR/ARHP Workforce Study (WFS): Adult Rheumatology Specialists in the United States: Effect of Gender and Generation	One of many studes on the ACR Workforce and Manpower study.